China’s pharmaceutical market will be an important source of growth for the entire global pharma industry over the next five years as regulatory reforms and improving healthcare coverage fuel the country’s growing demand for innovative drugs, Moody’s Investors Service said today in a new report. Companies with a major China presence already will most benefit thanks to their experience navigating the complex Chinese market and their established sales channels. While strong volume growth is expected for the growing number of drugs included on China’s National Drug Reimbursement List, inclusion on the list often implies heavy discounting, potentially placing pressure on profit margins unless offset by volume growth.
blaineonline.finance.blog 